Empliciti (elotuzumab)

Hermann Einsele (@H_Einsele; @Uniklinikum_Wue) shares the findings of a Phase III study investigating elotuzumab plus KRd versus KRd in patients with newly diagnosed #MultipleMyeloma: 👉 https://t.co/0MrwIVUtMX 👈 @EHA_Hematology #MMsm #ImmunoOnc #EHA2023 (@VJHemOnc)

Was good to present at #EHA23 the first results from our @MDAndersonNews IST on elotuzumab - clearly an active drug in MF - and an encore from #ASCO23 of the zilurgisertib (ACVR1/ALK2i) data showing anemia responses and hepcidin downregulation! #MPNSM (@bose_prithviraj)

#ASCO23 #mmsm Dr Knop: KRd vs elotuzumab and KRd in transplant-eligible patients with newly diagnosed #myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study - quads here to stay in upfront Rx!! @BldCancerDoc (@OncLive)

Didn't a cooperative group study elotuzumab in #MMsm before? Say, with a trial that started 12-11 years ago or something like that? (@RahulBanerjeeMD)

Elotuzumab continues to confuse us. After a string of failures- Elo improves post induction MRd negativity rates in a four vs three large randomized trial (n=579, Elo/KRd versus KRd, MRD neg 50% versus 35%). Whats going on here?! https://t.co/Fzf6EU6dDz… #mmsm #ASCO23 (@ManniMD1)

Well done #myeloma RT @EagleMyeloma: Why did Elotuzumab fail in #myeloma? 1. Soluble SLAMF7 interferes with the ADCC of Elo? 2. CD38 synapses with TC… https://t.co/MpnROVgcEj (@CyclingDoctor)

Why did Elotuzumab fail in #myeloma? 1. Soluble SLAMF7 interferes with the ADCC of Elo? 2. CD38 synapses with TCR, BCR, & CD16; so an Ab may interfere with TME? 3. Do Dara & Isa induce higher levels of complement-dependent cytotoxicity than Elo? #mmsm https://t.co/xx3YMSXzHf (@EagleMyeloma)

MM: False +ve IgG-Kappa M-spike on Darat (Anti-CD38) -> Biotinylated rCD38 and streptavidin-coated magnetic beads. What about Elotuzumab (Anti-SLAMF7)? @Ramikomrokji @Dr_AmerZeidan @CyclingDoctor @drhusnain01 @MyelomaSLC @Myeloma_Doc @szusmani @SLentzsch @KRakszawski @myelomaMD (@dawood_findakly)

Trial in progress: anti-SLAMF7 elotuzumab in JAK2-mutated myelofibrosis w/ @bose_prithviraj of @MDAndersonNews Watch: 👉https://t.co/A7PG0wSgcn👈 #ASH21 @ASH_hematology #HemOnc #LymSM #LeuSM #MMsm (@VJHemOnc)